Therefore, we can conclude that although blockade of IL-6 and IL-6 signaling have been shown to be effective in treating several inflammatory diseases (e.g., tocilizumab for rheumatoid arthritis and inflammatory bowel disease [21, 22]), its effect in patients with DM should be limited. Here, IL6 is linked to inflammatory bowel disease.